Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric XXXX .

@entity1 @entity137 @entity2600 @entity1264 @entity11
BACKGROUND: Management of low-grade @entity11 (LGG) can be a challenge, particularly when not resectable and refractory or recurrent following standard treatments. We undertook a retrospective analysis of 2 institutions' experiences treating @entity1 for refractory or progressive LGG with bevacizumab-based therapy (BBT). PROCEDURE: Inclusion criteria were @entity1 younger than 18 years of age who had previously failed one or more lines of therapy. Treatment was intravenous bevacizumab 10 mg/kg and intravenous @entity2600 125 to 150 mg/m every 2 weeks. RESULTS: Sixteen @entity1 (median age of 8.6 y), 5 with @entity1264 were treated between 2009 and 2013. Median duration of treatment was 12 months (range, 3 to 45 mo). Seven @entity1 (44%) showed clinical improvement (3 @entity1 within a month) and 8 @entity1 (50%) remained clinically stable during BBT. Imaging studies showed 3 (19%) had a partial response, 11 (69%) stable disease, and 2 (12%) had progressive disease. Four @entity1 had progressive disease after stopping BBT (median duration of 5 mo). Three of these 4 were able to be retreated with BBT and all achieved an objective response. Treatment was well tolerated with no grade 3 or 4 @entity137 related to bevacizumab. @entity2600 was discontinued in 4 @entity1 because of grade 2-3 @entity137 . CONCLUSIONS: We conclude that BBT is well tolerated and led to disease control in @entity1 with refractory or recurrent cases of LGG. Retreatment with BBT led to disease control in most of these cases. Larger, prospective studies are warranted to confirm these results.
